Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.

Abstract

MenB-FHbp is a meningococcal serogroup B vaccine. Persistence of hSBA titers against 4 diverse test strains≤4years after a 2-dose MenB-FHbp primary series and≤26months after a booster dose administered 4years post-primary has been demonstrated. Here, we developed a power law model (PLM) to estimate the persistence of hSBA titers up to 5years after a MenB-FHbp primary series and a booster dose using hSBA data from previous MenB-FHbp clinical trials in healthy adolescents. The PLM-predicted hSBA titers closely followed observed values after a 0, 6month MenB-FHbp primary series and a booster dose 4years later. At 5years post-primary and 5years post-booster, the PLM predicted that 15.2 %-50.0 % and 51.2%-70.9% of individuals, respectively, would have hSBA titers≥1:8 or 1:16. The PLM supports that the persistence of hSBA titers is maintained for at least 5years post-primary MenB-FHbp vaccination and post-booster.